menu
BCM - Baylor College of Medicine

Giving life to possible

Clinical Trials

Administration of LMP Specific Cytotoxic T-lymphocytes to Patients with Relapsed EBV-Positive Hodgkin’s disease (ALCI) (H-9936)

H-9936: Administration Of LMP Specific Cytotoxic T-Lymphocytes To Patients With Relapsed EBV-Positive Hodgkin Disease (ALCI): This study uses autologous EBV specific T-Lymphocytes targeting the EBV proteins LMP1 and LMP2 to treat lymphoma.

For more information:http://www.clinicaltrials.gov/ct2/show/NCT00671164